# Estimation of the Effect of Multiple Dose Ritlecitinib (PF-06651600) on the Pharmacokinetics of a Single Dose of Caffeine in Healthy Participants

> **NCT04655040** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 12 (actual)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** Caffeine
- **OTHER:** Ritlecitinib

## Key facts

- **NCT ID:** NCT04655040
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-18
- **Primary completion:** 2021-03-05
- **Final completion:** 2021-03-05
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2021-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04655040

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04655040, "Estimation of the Effect of Multiple Dose Ritlecitinib (PF-06651600) on the Pharmacokinetics of a Single Dose of Caffeine in Healthy Participants". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04655040. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*